Advanced Therapies Week 2022 | Future developments in targeted cell therapies for autoimmune diseases

Samik Basu, MD, Cabaletta Bio, Philadelphia, PA, provides a brief overview of cell therapies under development at Cabaletta Bio for various autoimmune diseases, including muscle-specific tyrosine kinase (MuSK) myasthenia gravis, and mucosal and mucocutaneous pemphigus vulgaris. Cell therapies for progressive membranous nephropathy, mediated by PLA2R-positive antibodies, are additionally under investigation. This interview took place at Advanced Therapies Week 2022.